Dale A. Cumming, Ph.D.

 

 

 

Dr. Cumming has 25+ years of experience in biotechnology, including 10 years  with Genetics Institute Inc., where he held a number of senior positions both in Product Development and in Discovery Research, working on both recombinant protein (e.g. EPO, novel tPAs, and Factor VIII) and small molecule therapeutics.  Subsequently,  he served as VP, Discovery Research at GlycoDesign Inc.  GlycoDesign was focused upon the identification and development of small molecule inhibitors of human glycosidases and glycosyltransferases for the treatment of cancer, inflammation and infectious disease. Later, Dr. Cumming was co-founder and CEO of Translational Medicines, Inc., a Boston biotech start-up focused upon developing therapeutics for cancer and inflammation by modulating the trafficking of immune and adult stem cells. Most recently, Dr. Cumming has also served as Director of Scientific Evaluations (and then CSO) for the nonprofit drug discovery and development corporation, the International Consortium on Anti-Virals.  In this role, he has been pursuing novel protein and small-molecule therapeutics for the treatment of pandemic influenza, dengue fever virus and other arboviruses, hepatitis C, and HIV.

 

Dr. Cumming began his research training as an undergraduate at the Dight Institute of Human Genetics and received his B.S. (summa cum laude) in Biochemistry from the College of Biological Sciences, University of Minnesota.  He received his Ph.D. in Molecular Biology from Vanderbilt University.  Dr. Cumming completed his training with post-doctoral stints at Vanderbilt University and the University of Toronto.